We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Progesterone Should Be Considered a Treatment Option in TBI

By HospiMedica International staff writers
Posted on 13 Jan 2010
A new commentary recommends that progesterone (PROG)--a naturally occurring hormone found in both males and females that can protect damaged cells in the central and peripheral nervous systems--be considered a viable treatment option for traumatic brain injury (TBI). More...


Researchers at Emory University (Atlanta, GA, USA) propose that injected or infused progesterone be considered as a treatment option for head trauma and central nervous system injuries. The researchers cited 100 preclinical studies and 2 clinical trials showing the hormone's beneficial effects on brain and central nervous system injuries, including TBI. Progesterone, they claim, protects against oxidative stress and immune inflammatory rejection reactions, as well as regulating neuronal development, mechanisms by which the hormone may hold promise in the treatment of traumatic and degenerative disorders of the brain and central nervous system. The commentary was published in the January 2010 issue of the American Journal of Roentgenology (AJR).

"Growing evidence indicates that postinjury administration of PROG in a variety of brain damage models can have beneficial effects, leading to substantial and sustained improvements in brain functionality,” said lead author Donald G. Stein, Ph.D., of the department of emergency medicine, "Given its relatively high safety profile, its ease of administration, its low cost and ready availability, progesterone should be considered a viable treatment option - especially because, in brain injury, so little else is currently available.”

Although it is widely considered a "sex steroid," PROG is also a protection hormone. It is naturally present in small but measurable amounts in the brains of males and females, and human brain tissue is loaded with progesterone receptors. Laboratory studies suggest that progesterone is critical for the normal development of neurons in the brain and exerts protective effects on damaged brain tissue by significantly reducing the area of necrotic cell death, improving behavioral outcomes, and protect neurons distal to the injury site. A U.S. national multicenter, randomized, double-blind study, coined ProTECT III, is planning to enroll 1,140 patients over five years at 17 medical centers across the United States to examine the neuroprotective effects of PROG.

Related Links:

Emory University



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.